New Delhi, Jul 14 (PTI) Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Icatibant Injectable, indicated for treatment of acute attacks of hereditary angioedema - a rare genetic condition - in adults.

Cipla's Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire's Firazyr, the company said in a regulatory filing.

Also Read | Poco M2 Pro Online India Sale Today at 12 Noon via Flipkart, Check Prices & Offers.

The firm said "it has received final approval for its abbreviated new drug application for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration".

Quoting IQVIA (IMS Health) data, Cipla said Firazyr and its generic equivalents had US sales of approximately USD 270 million for the 12-month period ending May 2020.

Also Read | 2020 Hyundai Tucson Facelift Launching Today in India; Watch Live Streaming of Hyundai's New SUV Launch Event.

Shares of Cipla were trading 0.49 per cent higher at Rs 641.25 apiece on the BSE.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)